Cynapsus Therapeutics (CYNA): $0.36 million was the positive money flow into the stock on Friday and the up/down ratio of ticks was also in favor of the bulls at 1.2. The value of trades done on upticks was $2.22 million, whereas, trades done on downticks were valued at $1.86 million. Money flows are calculated as the dollar value of composite uptick trades minus the dollar value of downtick trades. large traders, also sometimes called as the smart money, block traded $0 million worth stocks on upticks, which is a bullish indication. The money flow in block trades was $0 million. Cynapsus Therapeutics (CYNA) fell $0.01 traded at $39.69, a change of -0.03% over the previous day. The stock is 114.42% for the week.
Institutional Investors own 60.48% of Cynapsus Therapeutics shares.
Cynapsus Therapeutics (NASDAQ:CYNA): stock was range-bound between the intraday low of $39.68 and the intraday high of $39.71 after having opened at $39.7 on Fridays session. The stock finally closed in the red at $39.7, a loss of -0.05%. The stock remained in the red for the whole trading day. The total traded volume was 803,205 shares. The stock failed to cross $39.71 in Fridays trading. The stocks closing price on Thursday was $39.7.
Cynapsus Therapeutics (CYNA) : Traders are bullish on Cynapsus Therapeutics (CYNA) as it has outperformed the S&P 500 by a wide margin of 135.24% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 113.3%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 114.37% in the last 1 week, and is up 134.93% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
Cynapsus Therapeutics Inc. is a Canada-based clinical-stage, specialty pharmaceutical company. The Company is engaged in developing a sublingual thin filmstrip to manage OFF episodes associated with Parkinsons disease. The Companys drug candidate is APL-130277, which is a reformulation of apomorphine. The drug is an approved acute drug in the United States, Europe, Japan and other countries. The Company completed a CTH-105 Phase II clinical trial comprising approximately 16 people with Parkinsons disease.